Biocon

India’s Biocon spinning off its R&D division

John Carroll — Mon, 07 Jul 2008 10:51:39 -0400

India's Biocon is following the footsteps of a lineup of the subcontinent's biopharma companies in spinning off its R&D operations into a separate company. Sun, Wockhardt and Ranbaxy have all announced similar plans, which analysts say can help attract investors into the sector. Biocon's Kiran Mazumdar Shaw also said that Biocon is also preparing to establish its own tablet formulation manufacturing facility. That work has been done by a contract manufacturer.

- check out the story from the Economic Times

SPOTLIGHT: Biocon establishing R&D sub

Mon, 28 Apr 2008 06:59:53 -0400

India's Biocon says it will transfer four molecules to a new R&D subsidiary, resisting a trend in the subcontinent of spinning off R&D into a new company. Its researchers are working on new drugs for diabetes, cardiovascular, inflammation, oncology and endocrinology. Report

SPOTLIGHT: Biocon denies buyout report

Mon, 14 Apr 2008 06:59:53 -0400

Biocon caused a stir this morning after an Indian financial newspaper claimed the country's biggest biotech was nearing a $400 million buyout deal with a U.S. company. But Biocon executives moved quickly to squelch the story, saying the report was "speculative" and inaccurate. Report